Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, Zurich, Switzerland.
Virchows Arch. 2012 Jan;460(1):3-8. doi: 10.1007/s00428-011-1179-6. Epub 2011 Dec 6.
In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.
2011 年 2 月，来自欧洲不同部门的一组病理学家在瑞士苏黎世开会，讨论个性化医学时代病理学的机遇和挑战。会议的主要议题包括评估病理学在个性化医学中的作用、其在其他对个性化医学感兴趣的生物医学学科中的未来形象以及伴随诊断的发展。还讨论了用于临床实践的基因组分析的新技术的相关性。与会者认识到，病理学界应该在伴随诊断和新兴的下一代测序和全基因组分析领域采取更多举措。与会者的共识是，病理学界必须动员起来，为个性化医学的未来做出更大的贡献。病理学家应该意识到新技术的挑战和分析机会。还讨论了临床试验设计以及保险和报销问题的挑战。病理学界有责任引导医学同仁接受这个新的基因组医学领域。如果不做出这一努力，病理学这一学科就有可能失去其在分子组织诊断学方面的关键地位。
